Trial intelligence / Profile preview

Neratinib extended intensive therapy after adjuvant anti-HER2 treatment in high-risk early or locally advanced HER2-positive breast cancer

ChiCTR2500107226Phase 4Not yet recruiting

Sponsor

Shandong Provincial Hospital Affiliated to Shandong First Medical University

Start

Aug 2025

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1